Showing 6291-6300 of 9998 results for "".
- Tremfya Five-Year Data Show No New Safety Signalshttps://practicaldermatology.com/news/tremfya-five-year-data-show-no-new-safety-signs/2461016/New data published in the
- FDA Accepts sNDA for Incyte's Opzelura for Vitiligohttps://practicaldermatology.com/news/fda-accepts-snda-for-incytes-opzelura-for-vitiligo/2461009/FDA has accepted for Priority Review the supplemental New Drug Application (sNDA) for ruxolitinib cream 1.5% (Opzelura™) a topical JAK inhibitor from Incyte, as a potential treatment for adolescents and adults with vitiligo. The sNDA is supported by data from the Phase 3 TRuE-V cl
- FDA Approves Higher Dilution in New Sculptra Labelhttps://practicaldermatology.com/news/fda-approves-higher-dilution-in-new-sculptra-label/2461007/A new FDA-approved label for Sculptra® (injectable poly-L-lactic acid (PLLA)) from Galderma includes higher dilution, the addition of immediate use reconstitution, new injection techniques, and the optional addition of lidocaine. Sculptra is the first and only FDA-approved PLLA facial in
- Tapinarof Improves Plaque Psoriasis in Phase 3 Trialshttps://practicaldermatology.com/news/tapinarof-improves-plaque-psoriasis-in-phase-3-trials/2461004/Tapinarof performed well in two Phase 3 plaque psoriasis trials, according to research published in the New England Journal of Medicine. “This study report
- JAK Inhibitor Combo Shows Promise in Alopecia Areatahttps://practicaldermatology.com/news/jak-inhibitor-combo-shows-promise-in-alopecia-areata/2461002/Ritlecitinib and brepocitinib show significant improvement in scalp alopecia areata biomarkers, according to a phase 2a clinical trial published inthe Journal of Allergy and Clinical Immunology. Rese
- Cosmetic Surgery Forum Kicks Off in Nashvillehttps://practicaldermatology.com/news/cosmetic-surgery-forum-kicks-off-in-nashville/2461001/The no-nonsense presentations and candid audience contributions are center stage in Nashville as Cosmetic Surgery Forum kicks off with a live meeting after a hiatus last year, due to COVID-19 concerns. “We are ready to educate, inform, and have great discussions about topics that
- The Proactiv Company Rebrands to Alchemee, Expands Skincare Offeringshttps://practicaldermatology.com/news/the-proactiv-company-rebrands-to-alchemee-expands-skincare-offerings/2460998/The Proactiv Company is rebranding and repositioning under the new name Alchemee. Alchemee will cater to a multitude of skin concerns, and focus not only on consumers' needs, but on meeting them where they are along their journey through both innovation and an omni-channe
- ASDSA Honorees Recognized for Engagement in Initiatives that Benefit Dermatologic Surgery and Patientshttps://practicaldermatology.com/news/asdsa-honorees-recognized-for-engagement-in-initiatives-that-benefit-dermatologic-surgery-and-patients/2460995/The American Society for Dermatologic Surgery Association (ASDSA) announced the recipients of its annual awards this week during the ASDS / ASDSA Virtual Annual Meeting. ASDSA is proud to recognize its members who contribute significant time and expertise advocating for patient safety,
- Novel Lyme Vaccine Shows Promise in Early Researchhttps://practicaldermatology.com/news/novel-lyme-vaccine-shows-promise-in-early-research/2460994/Yale University researchers have developed a novel vaccine that in guinea pigs offers protection against infection by the bacterium that causes Lyme disease and may also combat other tick-borne diseases, they report in the journal Science Translational Medicine. Instead of trig
- Abreva Launches #StopBullyingYourself Campaign for People with Cold Soreshttps://practicaldermatology.com/news/abreva-launches-stopbullyingyourself-campaign-for-people-with-cold-sores/2460993/People with cold sores tend to beat themselves up, according to a new survey from Abreva. As many as 80 percent of people with cold sores feel misunderstood and want others to know it is a common affliction and that cold sores do not mean that they are